Serotonin (5HT) is a biologically active amine with diverse roles in the mammalian organism. Developmental alterations in 5HT homeostasis could lead to exposure of the developing brain to non-optimal serotonin concentrations that may result in developmental and behavioral deficits. In order to explore the molecular basis of the effects of developmental disturbances on 5HT metabolism on adult central 5HT homeostasis, observed in our previous studies, we measured changes in gene expression of the neuronal 5HT-regulating proteins in adult animals after perinatal treatment with the immediate 5HT precursor 5-hydroxytryptophan (5HTP, 25 mg/kg), or monoamine oxidase (MAO) inhibitor tranylcypromine (TCP 2 mg/kg), during the period of the most intensive development of 5HT neurons -from gestational day 12 until postnatal day 21. Adult animals were sacrificed and the relative mRNA levels for tryptophan hydroxylase 2, MAO A, MAO B, receptors 5HT 1A and 5HT 2A , 5HT transporter (5HTT) and vesicular monoamine transporter (VMAT) were determined in the raphe nuclei region and prefrontal cortex using Real-Time Relative qRT-PCR. In comparison to the saline treated animals, treatment with 5HTP caused mild but significant increase in MAO A and MAO B mRNA abundance. TCP-treated animals, besides an increase in mRNA abundance for both MAO genes, displayed significantly increased 5HTT and VMAT2 mRNA levels and significantly decreased 5HT 1A receptor mRNA levels. Our results suggest that perinatal exposure of rats to 5HTP, and especially TCP, induces long-lasting/permanent changes in the expression of 5HT-regulating genes, that presumably underlie 5HT-related neurochemical and behavioral changes in adult animals.
Introduction
Serotonin (5-hydroxytryptamine, 5HT) is a biologically active amine with diverse roles in the mammalian organism, where it is present both in the brain and peripheral tissues. In the periphery, serotonin serves as a regulator of food intake, gastrointestinal, endocrine and cardiovascular function, and as platelet activator [1] . In the developing brain, serotonin serves as a key regulator of serotonergic outgrowth and maturation of target regions [2] .
In the mature brain it acts as a neurotransmitter modulating function and plasticity [3, 4] . The blood brain barrier, which is not permeable to 5HT, separates the central and peripheral 5HT-compartments allowing for independent regulation of 5HT homeostases maintained through the action of 5HT-regulating proteins.
Each of the 5HT-regulating proteins in the serotonergic synapse has a homologue in the peripheral compartment. Some are present as isoforms encoded by separate genes.
The enzyme tryptophan hydroxylase (TPH)
is responsible for the rate-limiting step of serotonin synthesis. TPH1 exists mostly in the enterochromafin cells of the intestinal mucosa [5] and TPH2 in 5HT synthesizing neurons [6] . The vesicular monoamine transporter (VMAT) is responsible for the cellular 5HT accumulation and storage in platelet (VMAT1) or neuronal (VMAT2) vesicles [7] . Other 5HT-elements are encoded by the same genes centrally and peripherally. The serotonin transporter (5HTT) is important for serotonin transport into platelets, and reuptake into the presynaptic neuron [8] . Serotonin receptors 1A (5HT 1A R) and 2A (5HT 2A R) act as pre-and post-synaptic regulators of synaptic 5HT action [9] , while those present on the cells of the intestinal mucosa may be involved in the regulation of 5HT release from the gut [10] . 5HT 2A r is also present on the platelet membrane and is involved in the process of aggregation during which 5HT is released from the platelets. In both compartments, 5HT is converted into 5-hydroxyindolacetic acid (5HIAA) through the oxidative deamination catalyzed by the mitochondrial enzyme monoamine oxidase (MAO) [11] . MAO comes in two isoforms: MAO A preferentially oxidizes serotonin and norepinephrine, MAO B phenylethylamine, while dopamine and tyramine represent substrates for both isoenzymes.
During fetal and early postnatal development, the blood brain barrier is not fully formed and serotonin can freely cross from the peripheral compartment into the brain and influence the development of the neuronal 5HT system [12] .
In fact, peripheral 5HT levels seem to have a role during pregnancy, as maternal [13] and placental [14] serotonin levels were shown to influence fetal brain development in mice.
Therefore, it may be assumed that altered 5HT model of autism [15] . The second approach has been widely employed in order to investigate the consequences of perinatal exposure to SSRI [16] . The long-term effects of perinatal alterations in serotonin metabolism have been far less studied. We therefore opted for the third approach using the immediate precursor 5-hydroxytryptophan (5HTP) to facilitate 5HT synthesis, or a MAO inhibitor tranylcypromine (TCP) to impede 5HT degradation, during the period of most intensive development of 5HT neurons [17] . In our previous studies we demonstrated that: a) during treatment, 5HTP
significantly elevated 5HT concentrations in the peripheral but not in the central 5HT compartment [18] , while its long-term effect (in adult animals) was mild but significant reduction in cortical 5HT levels without any effect on 5HT metabolism [19] ; b) during treatment, TCP significantly elevated 5HT levels both, in the brain and the periphery [20] , while its long-term effect was a robust decrease in cortical and midbrain 5HT levels accompanied with markedly increased 5HT degradation [19] ; and c) animals from both groups displayed reduction in anxiety-like behavior that corresponded with the degree of the reduction in 5HT function [21] .
The aim of the present study was to explore 
Experimental Procedures
Wistar rats were bred and raised at the Division of Biology of the Faculty of Science, University of Zagreb, according to the procedure described elsewhere [18, 20] . In summary, nulliparous cDNA was stored at -20°C until further processing.
Relative expression of the genes included in Table 1 was assessed through qRT-PCR using the 
Results
Relative abundance of mRNAs for serotonin In the frontal cortex (Table 3) groups, and complexity of experimental design. As described earlier [18, 20] , doses were determined according to literature data and to the results of our experiments on adult animals.
5HTP was administered in a dose sufficient to raise 5HT concentrations without causing the serotonin syndrome, while the given dose of TCP was expected to effectively block most, but not all of the 5HT degradation.
Sites of expression of 5HT-regulating genes
There is little data available on the levels of expression of genes coding for the 5HT-regulating elements in various brain regions.
We therefore first compared relative mRNA abundance for these genes between the site of 5HT neuronal somas and the site of 5HT neuronal endings in the control group of rats.
All of the investigated genes were expressed both in the RNR and PFC. Our findings are in line with the reported detection of mRNA in both regions for 5HTT [28] , TPH2 [29] , 5HT 1A R 
The effects of pharmacological treatments on the expression of 5HT-regulating genes
Two different 5HT enhancers interfering with 5HT metabolism were used in this study. The first one was the immediate 5HT precursor, which elevated 5HT levels without acting that genes which regulate 5HT metabolism should be considered as potential candidates in 5HT-related behavioral disorders. Indeed, our findings in autistic subjects indicated that disrupted 5HT homeostasis is related to alterations in 5HT metabolism rather than 5HT uptake [45, 46] . Second, the developmental disbalance induced in both 5HT-compartments 
